-
1
المؤلفون: Peggy Stock, Bruno Christ, Matthias M. Dollinger
المصدر: Hepatology. 53:1388-1390
مصطلحات موضوعية: Pathology, medicine.medical_specialty, Hepatology, medicine.medical_treatment, Cancer, Cell cycle, Biology, medicine.disease, Radiation therapy, Apoptosis, Cell culture, Cancer stem cell, medicine, Cancer research, CD90, Liver cancer
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::23ee9ed00d39889bbb44fe0af52d3640Test
https://doi.org/10.1002/hep.24222Test -
2
المؤلفون: Tom M. Ganten, M. A. Woerns, Jens T. Siveke, Ulrich M. Lauer, R. Jankowsky, A. Mais, Bernd Hentsch, Henning Wege, B. Hauns, Marius Horger, Edoardo G. Giannini, Matthias M. Dollinger, Vincenzo Montesarchio, Michael Bitzer, Max E. Scheulen, Guido Gerken
المصدر: Journal of Clinical Oncology. 30:262-262
مصطلحات موضوعية: Oncology, Sorafenib, Cancer Research, medicine.medical_specialty, business.industry, Cancer, medicine.disease, Surgery, chemistry.chemical_compound, Tolerability, Resminostat, chemistry, Hepatocellular carcinoma, Internal medicine, medicine, HDAC inhibitor, In patient, business, Progressive disease, medicine.drug
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::15c5121572a995bacc095f3bdb948545Test
https://doi.org/10.1200/jco.2012.30.4_suppl.262Test -
3
المؤلفون: A. Mais, Bernd Hentsch, Guido Gerken, Tom M. Ganten, M. A. Woerns, Jens T. Siveke, Michael Bitzer, Max E. Scheulen, Ulrich M. Lauer, Matthias M. Dollinger, R. Jankowsky, B. Hauns, Marius Horger, Matthias P. Ebert
المصدر: Journal of Clinical Oncology. 29:e13603-e13603
مصطلحات موضوعية: Oncology, Sorafenib, Cancer Research, medicine.medical_specialty, Pathology, business.industry, Cancer, medicine.disease, chemistry.chemical_compound, Phase i ii, Resminostat, chemistry, Internal medicine, Hepatocellular carcinoma, medicine, HDAC inhibitor, In patient, business, medicine.drug
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::aaf83520c05a81a8dd3f3d3e5aa99b67Test
https://doi.org/10.1200/jco.2011.29.15_suppl.e13603Test -
4
المؤلفون: Bernd Hentsch, Matthias P. Ebert, Michael Bitzer, Matthias M. Dollinger, M. A. Woerns, Marius Horger, Tom M. Ganten, A. Mais, B. Hauns, Ulrich M. Lauer
المصدر: Journal of Clinical Oncology. 29:275-275
مصطلحات موضوعية: Oncology, Sorafenib, Cancer Research, medicine.medical_specialty, business.industry, Cancer, Pharmacology, medicine.disease, chemistry.chemical_compound, Resminostat, chemistry, Tolerability, Internal medicine, Hepatocellular carcinoma, Medicine, In patient, Dosing, business, Progressive disease, medicine.drug
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::5c9c0dd87d023a8660bb00dbabc1333eTest
https://doi.org/10.1200/jco.2011.29.4_suppl.275Test